MedTrace Logo

Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis

NCT02738775 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2021-07-15

Study results available
· View outcomes & findings →

Summary

This study evaluates the use of single agent ublituximab, a novel monoclonal antibody, in participants with relapsing forms of multiple sclerosis.

Conditions

Interventions

BIOLOGICAL

Ublituximab

Administered as an IV infusion.

DRUG

Placebo

Sponsors & Collaborators

  • TG Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Edward Fox, MD, PhD · Central Texas Neurology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-27
Primary Completion
2017-09-27
Completion
2018-08-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02738775 on ClinicalTrials.gov